{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-119520","form_type":"8-K","ticker":null,"cik":"0001664106","company_name":"LogicBio Therapeutics, Inc.","filed_at":"2022-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.624748+00:00","generated_at":"2026-06-21T17:32:19.068046+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.03","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Alexion completes acquisition of LogicBio for $2.07/share; shares to be delisted","bullets":["Tender offer closed with 26.95M shares (81.76%) validly tendered; Merger completed under DGCL Section 251(h).","Each share converted into $2.07 cash, less withholding; options and warrants cancelled per Merger Agreement.","All prior board members and executive officers ceased; new directors and officers from Purchaser took over.","Loan and Security Agreement with Oxford Finance terminated and fully repaid upon closing.","LogicBio requested Nasdaq delisting and intends to file Form 15 to suspend SEC reporting obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-119520","json":"https://secwatch.observer/filing/0001104659-22-119520.json","markdown":"https://secwatch.observer/filing/0001104659-22-119520.md","text":"https://secwatch.observer/filing/0001104659-22-119520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/tm2230653d5_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T17:32:19.068046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26be8b1f3e","claim":"Mark Kay departed as Director at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Leon Chen, Mark Enyedy, J. Jeffrey Goater, Susan R. Kahn, Daphne Karydas, Mark Kay, Richard Moscicki and Michael Wyzga ceased to serve on the Company’s board of directors and the committees of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2efb2fca9a","claim":"Daphne Karydas departed as Director at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Leon Chen, Mark Enyedy, J. Jeffrey Goater, Susan R. Kahn, Daphne Karydas, Mark Kay, Richard Moscicki and Michael Wyzga ceased to serve on the Company’s board of directors and the committees of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"35b8e273ed","claim":"J. Jeffrey Goater departed as Director at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Leon Chen, Mark Enyedy, J. Jeffrey Goater, Susan R. Kahn, Daphne Karydas, Mark Kay, Richard Moscicki and Michael Wyzga ceased to serve on the Company’s board of directors and the committees of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3a113bf0ff","claim":"Richard Moscicki departed as Director at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Leon Chen, Mark Enyedy, J. Jeffrey Goater, Susan R. Kahn, Daphne Karydas, Mark Kay, Richard Moscicki and Michael Wyzga ceased to serve on the Company’s board of directors and the committees of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"61fa72ac7c","claim":"Frederic Chereau departed as other_named_officer at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Josh Blacher, Daniel Gruskin and Mariana Nacht ceased to be executive officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"}],"fact_type":"executive_change"},{"claim_id":"6f6a92f61d","claim":"Michael Wyzga departed as Director at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Leon Chen, Mark Enyedy, J. Jeffrey Goater, Susan R. Kahn, Daphne Karydas, Mark Kay, Richard Moscicki and Michael Wyzga ceased to serve on the Company’s board of directors and the committees of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"700eb7faeb","claim":"Susan R. Kahn departed as Director at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Leon Chen, Mark Enyedy, J. Jeffrey Goater, Susan R. Kahn, Daphne Karydas, Mark Kay, Richard Moscicki and Michael Wyzga ceased to serve on the Company’s board of directors and the committees of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7c53dc3428","claim":"Daniel Gruskin departed as other_named_officer at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Josh Blacher, Daniel Gruskin and Mariana Nacht ceased to be executive officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"}],"fact_type":"executive_change"},{"claim_id":"86f7cb869c","claim":"Frederic Chereau departed as Director at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Leon Chen, Mark Enyedy, J. Jeffrey Goater, Susan R. Kahn, Daphne Karydas, Mark Kay, Richard Moscicki and Michael Wyzga ceased to serve on the Company’s board of directors and the committees of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9e86c4c868","claim":"Josh Blacher departed as other_named_officer at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Josh Blacher, Daniel Gruskin and Mariana Nacht ceased to be executive officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"}],"fact_type":"executive_change"},{"claim_id":"9fe44bca01","claim":"Mariana Nacht departed as other_named_officer at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Josh Blacher, Daniel Gruskin and Mariana Nacht ceased to be executive officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"}],"fact_type":"executive_change"},{"claim_id":"da427d2bc6","claim":"Mark Enyedy departed as Director at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Leon Chen, Mark Enyedy, J. Jeffrey Goater, Susan R. Kahn, Daphne Karydas, Mark Kay, Richard Moscicki and Michael Wyzga ceased to serve on the Company’s board of directors and the committees of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f14c390484","claim":"Leon Chen departed as Director at LogicBio Therapeutics, Inc..","evidence_excerpt":"each of Frederic Chereau, Leon Chen, Mark Enyedy, J. Jeffrey Goater, Susan R. Kahn, Daphne Karydas, Mark Kay, Richard Moscicki and Michael Wyzga ceased to serve on the Company’s board of directors and the committees of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"607ee552668a567eb8bd24edcb7a21f938d2aeb0","claim":"LogicBio Therapeutics, Inc.: Amended and restated certificate of incorporation and bylaws in connection with merger consummation.","evidence_excerpt":"the Company’s certificate of incorporation and its bylaws were amended and restated in their entirety, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"68c69e29777b3334720ec3dbde07e78f74bb491f","claim":"LogicBio Therapeutics, Inc. completed an acquisition involving Alexion Pharmaceuticals, Inc. for $2.07 per Share in cash (closed 2022-11-16).","evidence_excerpt":"waiver of certain other conditions, any and all of the issued and outstanding shares of common stock, par value $0.0001 per share (the “ Shares ”), of the Company at a price of $2.07 per Share, to the seller in cash, without interest (the “ Offer Price ”) , less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":1.0,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Alexion Pharmaceuticals, Inc."},{"label":"Consideration","value":"$2.07 per Share in cash"},{"label":"Closing","value":"2022-11-16"}],"fact_type":"ma_transaction"},{"claim_id":"666d8be4a9274a83e29aa7fbe1838fed10e2dbeb","claim":"LogicBio Therapeutics, Inc. terminated Loan and Security Agreement with Oxford Finance LLC, as collateral agent, the lenders party thereto, the Company and LogicBio Australia Pty Limited (effective 2022-11-16).","evidence_excerpt":"On November 16, 2022, the Company terminated that certain Loan and Security Agreement, dated July 2, 2019, among Oxford Finance LLC, as collateral agent, the lenders party thereto, the Company and LogicBio Australia Pty Limited, as amended, modified, supplemented, restated or amended and restated through the date of the Merger Agreement, and repaid all the outstanding obligations in respect of principal, interest and fees thereunder.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oxford Finance LLC, as collateral agent, the lenders party thereto, the Company and LogicBio Australia Pty Limited"},{"label":"Effective","value":"2022-11-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}